Management of chronic hepatitis B in challenging patient populations

Liver International

Volumn 26, Issue SUPPL. 2, 2006, Pages 38-46

  Dore, Gregory J ^a   Guan, Richard ^b   Wasim Jafri, S M ^c   Sarin, Shiv V ^d   Keeffe, Emmet B ^e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c AGA KHAN UNIVERSITY   (Pakistan)

^d G B PANT HOSPITAL   (India)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Alanine aminotransferase; Chemotherapy; Children; Human immunodeficiency virus; Immunosuppression; Liver transplantation; Pregnancy; Special populations

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; STEROID; TENOFOVIR; VIRUS DNA;

ANTIBIOTIC RESISTANCE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD HEALTH CARE; COMORBIDITY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; ECHOGRAPHY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; REVIEW; RISK ASSESSMENT; SEROCONVERSION; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION;

EID: 33750729223     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01375.x     Document Type: Review

References (89)

1. Liaw Y F, Leung H, Guan R, Lau G K, Merican I, Asian-Pacific Consensus Working Parties on Hepatitis B. Asian-Pacific consensus statement of the management of chronic hepatitis B: An update. J Gastroenterol Hepatol 2003; 18: 239-45.
2. Liaw Y F, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
3. Liaw Y F, and ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: Treatment alert. Liver Int 2006, in press.
4. Liaw Y F. The current management of HBV drug viral resistance. J Clin Virol 2005; 34: S143-6.
5. Locarnini S. Molecular virology and the development of resistant mutants: Implications for therapy. Semin Liver Dis 2005; 25 (Suppl. 1): 9-19.
6. Leemans W F, Flink H J, Janssen H L, Niesters H G, Schalm S W, de Man R A. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 2006; 44: 507-11.
7. Peters M G, Hann H H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
8. Scotto G, Palumbo E, Fazio V, Tartaglia A, Saracino A, Angarano G. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B. New Microbiol 2005; 28: 193-7.
9. Lampertico P, Marzano A, Levrero M, et al. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2-year analysis of 604 patients [abstract]. Hepatology 2005; 42 (Suppl. 1): 591A.
10. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9.
11. Ghany M, Lutchman G, Kleiner D, et al. Lamivudine and adefovir versus adefovir alone for HBeAg-positive chronic hepatitis B [abstract]. Hepatology 2005; 42 (Suppl. 1): 591-2A.
12. Perrillo R, Hann H W, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
13. Liaw Y F, Lee C M, Chien R N, Yeh C T. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepatitis 2006; 13: 250-5.
14. Fung S K, Andreone P, Han S H, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937-43.
15. Yeon J E, Yoo W, Hong S P, et al. Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic hepatitis B patients treated with ADV. Gut 2006; February 4, epub ahead of print.
16. Lee Y S, Suh D J, Lim Y S, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-91.
17. van Bömmel F, Mauss S, Zollner B, et al. Long-term effect of tenofovir in the treatment of lamivudine-resistant hepatitis B virus infections in comparison to adefovir [abstract]. Hepatology 2005; 42 (Suppl. 1): 269A.
18. van Bömmel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
19. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, in press.
20. Colonno R, Rose R, Levine S, et al. Entecavir two year resistance update: No resistance observed in nucleoside naïve patients and low frequency resistance emergence in lamivudine refractory patients [abstract]. Hepatology 2005; 42: 573-4A.
21. Thibault V, Benhamou Y, Valantin M A, Brosgart C L, Xiong S. Long-term experience of adefovir dipivoxil add-on therapy in chronic hepatitis B patients co-infected with HIV and lamivudine-resistant HBV: Absence of adefovir resistance mutation selection [abstract]. Hepatology 2005; 42: 581A.
22. Brunelle M N, Jacquard A C, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.
23. Fung S K, Chae H B, Fontana R J, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.
24. Chu C M, Liaw Y F. Natural history differences in perinatally versus adult-acquired disease. Curr Hepat Rep 2004; 3: 123-31.
25. Kim H C, Nam C M, Jee S H, Han K H, Oh D K, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ 2004; 328: 983.
26. Yang P M, Chen D S, Lai M Y, et al. Clinicopathologic studies of asymptomatic HBsAg carriers: With special emphasis on carriers older than 40 years. Hepatogastroenterology 1987; 34: 251-4.
27. Chu C M, Hung S J, Lin J, Tai D I, Liaw Y F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal aminotransferase levels. Am J Med 2004; 116: 829-34.
28. Lai M, Hyatt B, Afdahl N. Role of liver biopsy in patients with normal ALT and high HBV DNA [abstract]. Hepatology 2005; 42: 720A.
29. Wang C, Deubner H, Shuhart M, Manasala J H, Corey L, Kowdley K. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection [abstract]. Hepatology 2005; 42 (Suppl. 1): 573A.
30. Nguyen M H, Trinh H, Garcia R T, Ahmed A, Keeffe E B. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation [abstract 1008]. Hepatology 2005; 42 (Suppl. 1): 593A.
31. Chandra R, Kapoor D, Agarwal S R, Malhotra V, Sakhuja P, Sarin S K. Profile of asymptomatic chronic HBV infection in India. Indian J Med Res 2002; 116: 50-7.
32. Tyagi P, Chauhan R, Kumar R, Sharma B C, Sarin S K. Normal ALT levels do not signify absence of histological injury or significant viremia in incidentally detected asymptomatic HBsAg positive subjects (IDAHS) and its correlation with HBV DNA levels. Indian J Gastroenterol. 2004; 23 (Suppl. 2): A56.
33. Liaw Y F, Tsai S L, Chien R N, Yeh C T, Chu C M. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32: 604-9.
34. Sarin S K, Sandhu B S, Sharma B C, Jain M, Singh J, Malhotra V. Beneficial effects of 'lamivudine pulse'therapy in HBeAg-positive patients with normal ALT. J Viral Hepat 2004; 11: 552-8.
35. Satpathy S K, Garg S, Chauhan R, et al. Profile of chronic hepatitis B birth infection in children in India. J Gastroenterol Hepatol 2006, in press.
36. Kerkar N, Shneider B L. Evolving approaches to the treatment of chronic hepatitis B virus infection in children. J Clin Gastroenterol 2005; 39: 7-9.
37. Jonas M M, Mizerski J, Badia I B, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-13.
38. Sokal E M, Kelly D A, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006; 43: 225-32.
39. Dikici B, Ozgenc F, Kalayci A G, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: A multicenter study. J Gastroenterol Hepatol 2004; 19: 127-33.
40. Hagmann S, Chung M, Rochford G, et al. Response to lamivudine treatment in children with chronic hepatitis B virus infection. Clin Infect Dis 2003; 37: 1434-40.
41. Artan R. Lamivudine monotherapy in children with immune-tolerant chronic hepatitis B virus. J Chemother 2005; 17: 198-202.
42. Grigorescu-Sido P, Calin L, Manasia R, et al. Results of interferon treatment in children with chronic hepatitis B. Rom J Gastroenterol 2002; 11: 285-90.
43. Kacprzak-Bergman I, Zaleska I, Gruszka J, Jasonek J. A longitudinal study of the efficacy of interferon therapy in children with chronic hepatitis B. Med Sci Monit 2002; 8: 805-14.
44. Kobak G E, MacKenzie T, Sokol R J, Narkewicz M R. Interferon treatment for chronic hepatitis B: Enhanced response in children 5 years old or younger. J Pediatr 2004; 145: 340-5.
45. Liberek A, Luczak G, Korzon M, et al. Tolerance of interferon-alpha therapy in children with chronic hepatitis B. J Paediatr Child Health 2004; 40: 265-9.
46. Guptan R C, Thankur V, Malhotra V, Sarin S K. Recombinant interferon therapy in Indian children with HBV related chronic liver disease. Indian Pediatr 2002; 39: 462-7.
47. Wang Z, Zhang J, Yang H, et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003; 71: 360-6.
48. Shiraki K. Perinatal transmission of hepatitis B virus and its prevention. J Gastroenterol Hepatol 2000; 15 (Suppl.): E11-5.
49. Yang H, Chen R, Li Z, et al. Analysis of fetal distress in pregnancy with hepatitis B virus infection. Zhonghua Fu Chan Ke Za Zhi 2002; 37: 211-3.
50. Khuroo M S, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat 2003; 10: 61-9.
51. Shapiro C N, Margolis H S. Impact of hepatitis B virus infection on women and children. Infect Dis Clin North Am 1992; 6: 75-96.
52. Beasley R P, Hwang L Y, Lee G C, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2: 1099-102.
53. Lo K J, Tsai Y T, Lee S D, et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 1985; 152: 817-22.
54. Wong V W, Ip H H, Reesnik H W, et al. Prevention of HBsAg carrier state in administration of hepatitis B vaccine and hepatitis B immunoglobin: double-blind randomized placebo-controlled study. Lancet 1984; 1: 921-6.
55. van Zonneveld M, van Nunen A B, Niesters H G, de Man R A, Schalm S W, Janssen H L. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepatitis 2003; 10: 294-7.
56. Van Nunen A B, de Man R A, Heijtink R A, Niesters H G, Schalm S W. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000; 32: 1040-1.
57. Kazim S N, Wakil S M, Khan L A, Hasnain S E, Sarin S K. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002; 359: 1488-9.
58. Yeo W, Johnson P J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
59. Simpson N D, Simpson P W, Ahmed A M, et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol 2003; 37: 68-71.
60. Lau G K, Yiu H H, Fong D Y, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.
61. Dai M S, Wu P F, Shyu R Y, Lu J J, Chao T Y. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004; 24: 540-6.
62. Hui C K, Cheung W W, Au W Y, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 11: 1597-603.
63. Keeffe E B, Dieterich D T, Han S B, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, in press.
64. Guan R. Treatment of chronic hepatitis B in HIV co-infected patients. Med J Malaysia 2005; 58 (Suppl. S5-2): 31-6.
65. Bodsworth N J, Cooper D A, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163: 1138-40.
66. Gilson R J, Hawkins A E, Beecham M R, et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 1997; 11: 597-606.
67. Colin J F, Cazals-Hatem D, Loriot M A, et al. Human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-10.
68. Thio C L, Seaberg E C, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohor Study (MACS). Lancet 2002; 360: 1921-6.
69. Matthews G V, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863-70.
70. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 221-40.
71. Huang A, et al. Entecavir in HIV-HBV co-infection: Week 48 results (ETV-038). Abstract H-415. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16-19, 2005. Washington, DC. Available at: http://www.hivandhepatitis.com/2005icr/ icaac/docs/011306_coinf2.html. Accessed June 5, 2006.
72. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001; 358: 718-23.
73. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44: 62-7.
74. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43: 548-55.
75. Dore G J, Cooper D A, Pozniak A L, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-92.
76. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-6.
77. Mutimer D. Review article: Hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006; 23: 1031-41.
78. Wai C T, Prabhakaran K, Wee A, et al. Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Hepatobiliary Pancreat Dis Int 2005; 4: 509-14.
79. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-8.
80. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transplant 2001; 7: 113-7.
81. Karademir S, Astarcioglu H, Akarsu M, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006; 38: 579-83.
82. Karasu Z, Ozacar T, Akyildiz M, et al. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 921-7.
83. Barcena R, Del Campo S, Moraleda G, et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant Proc 2005; 37: 3960-2.
84. Barcena R, Del Campo S, Moraleda G, et al. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 113-7.
85. Herreros de Tejada Echanojauregui A, Moreno Planas J M, Rubio Gonzalez E, et al. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. Transplant Proc 2005; 37: 1507-8.
86. Lo C M, Liu C L, Lau G K, Chan S C, Ng I O, Fan S T. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-13.
87. Schiff E R, Lai C L, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
88. Lee K H, Lee H L, Da Costa M, Lim S G. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transplant Proc 2004; 36: 2313-4.
89. Lok A S, Fung S K, Han S H, et al. Virological response and resistance to adefovir (ADV) therapy in liver transplant (OLT) patients [abstract]. Hepatology 2005; 42 (Suppl. 1): 232A.